Business Context and Reporting Period
This Form 8-K Current Report was filed by Clover Health Investments, Corp. on August 20, 2024. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial disclosure relates to director compensation:
- Director Compensation: Thomas L. Tran will receive a pro rata portion of the annual retainer for Board and Audit Committee service.
- Equity Grant: Mr. Tran was granted a restricted stock unit (RSU) award with a value of $200,000, pro-rated based on the number of days of service remaining in 2024.
Material Changes
The Board of Directors increased its size from eight to nine members with the appointment of Thomas L. Tran as a Class II director. Mr. Tran has been assigned to the Audit Committee. No material changes to financial operations or strategy were reported in this document.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. The document focuses solely on the appointment details and the execution of a standard indemnification agreement for the new director.
Investor Verification Checklist
- Verify the pro-rated calculation of the $200,000 RSU award based on the appointment date versus December 31, 2024.
- Review the attached press release (Exhibit 99.1) for additional context on the strategic rationale for the appointment.
- Confirm the updated Board composition and Audit Committee membership in subsequent filings.
- Note that this filing does not contain updated financial results; refer to the most recent 10-Q or 10-K for financial status.